In June of 1981 the first known cases of AIDS in the United States were reported. Currently there are over 1.7 million people in the United States infected with HIV-1, the virus which causes AIDS, and over more then 600,000 Americans have already died from this ultimately fatal disease. With 1.2 million Americans estimated to[…]
Life Extending Enfuvirtide Looks to Become a Successful Generic
Anti-Retroviral / Anti-HIV, Patent Expiration 2013, Patent Expiration 2015 Tags: AIDSHIVHIV infectionRitonavir Jun 27, 2012
Duloxetine Hydrochloride Effectual for Osteoarthritis Pain Management
Antidepressant, Drug Research & Development API, Patent Expiration 2013 Tags: Antidepressantserotonin May 29, 2012
Duloxetine Hydrochloride CAS# 136434-34-9, is also known as the brand name Cymbalta marketed by Lilly. This effective antidepressant will be going off patent in June of 2013. Duloxetine hydrochloride is currently approved to treat the following: clinical depression; peripheral diabetic neuropathy pain, or nerve pain in the hands, feet, arms, and legs from diabetes; generalized[…]
Sirolimus Continues to be Effective, Even When Thought to be Contraindicated
Drug Research & Development API, Immunosuppressant, Patent Expiration 2012, Patent Expiration 2013 Tags: hypertensionImmunosuppressantPfizerSirolimus May 21, 2012
As an immunosuppressant drug used to prevent transplant rejection, Sirolimus, CAS number 53123-88-9, is a macrolide. Particularly useful for kidney transplant patients, sirolimus is also known as the brand name Rapamune, which is marketed by Pfizer. The first patent for Rapamune is set to expire in October 2012. An addtional patent will expire in July[…]
